DK1649287T3 - Evaluering af vacciner med adjuvans - Google Patents

Evaluering af vacciner med adjuvans

Info

Publication number
DK1649287T3
DK1649287T3 DK04739011T DK04739011T DK1649287T3 DK 1649287 T3 DK1649287 T3 DK 1649287T3 DK 04739011 T DK04739011 T DK 04739011T DK 04739011 T DK04739011 T DK 04739011T DK 1649287 T3 DK1649287 T3 DK 1649287T3
Authority
DK
Denmark
Prior art keywords
antigen
solid phase
immunological activity
mixture
activity
Prior art date
Application number
DK04739011T
Other languages
Danish (da)
English (en)
Inventor
Peter Adler Wuertzen
Gitte Lund
Henrik Hugo Jacobi
Hans-Henrik Ipsen
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34276701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1649287(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alk Abello As filed Critical Alk Abello As
Application granted granted Critical
Publication of DK1649287T3 publication Critical patent/DK1649287T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK04739011T 2003-08-05 2004-07-28 Evaluering af vacciner med adjuvans DK1649287T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49302003P 2003-08-05 2003-08-05
DKPA200301130 2003-08-05
PCT/DK2004/000514 WO2005022157A1 (en) 2003-08-05 2004-07-28 Evaluation of adjuvanted vaccines

Publications (1)

Publication Number Publication Date
DK1649287T3 true DK1649287T3 (da) 2008-11-24

Family

ID=34276701

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04739011T DK1649287T3 (da) 2003-08-05 2004-07-28 Evaluering af vacciner med adjuvans

Country Status (12)

Country Link
EP (1) EP1649287B1 (de)
KR (1) KR101132439B1 (de)
CN (1) CN1829917B (de)
AT (1) ATE403867T1 (de)
AU (1) AU2004269076B2 (de)
CA (1) CA2532726C (de)
DE (1) DE602004015611D1 (de)
DK (1) DK1649287T3 (de)
ES (1) ES2310732T3 (de)
MX (1) MXPA06001382A (de)
PL (1) PL1649287T3 (de)
WO (1) WO2005022157A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006291835B2 (en) 2005-09-15 2012-04-05 Alk-Abello A/S A method for quantification of allergens
CN101351561B (zh) * 2005-11-24 2013-07-17 爱尔开-阿贝优公司 测量吸附变应原酶的酶活性的方法
CA2629923C (en) 2005-11-24 2014-10-14 Alk-Abello A/S A method of measuring enzymatic activity of adsorbed allergenic enzyme
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
EP2652511B8 (de) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Durchflusszytometrische analayse von metallsalzadsorbierten stoffen
WO2013046226A2 (en) * 2011-08-04 2013-04-04 Serum Institute Of India Ltd. A novel quantification method for vaccines
CN109752560A (zh) * 2019-02-28 2019-05-14 艾棣维欣(苏州)生物制药有限公司 一种佐剂生物活性的检测方法
CN113009052A (zh) * 2021-02-22 2021-06-22 中国食品药品检定研究院 水痘减毒活疫苗中β-内酰胺类抗生素的检测方法
EP4387594A4 (de) * 2021-08-17 2025-06-18 Innovar Scientific, Inc. Verfahren und systeme zur bewertung und konformitätsprüfung von impfstoffen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK140815B (da) * 1975-06-10 1979-11-19 Weeke Bengt Fremgangsmåde til påvisning eller bestemmelse af antistoffer i legemsvæsker ved hjælp af kendte antigener eller til bestemmelse af antigener ved hjælp af kendte antistoffer fra legemsvæsker samt et middel til anvendelse ved udøvelse af fremgangsmåden.
SU1746318A1 (ru) * 1990-06-05 1992-07-07 Институт полиомиелита и вирусных энцефалитов Способ определени концентрации белка Е вируса клещевого энцефалита в препаратах вакцины, сорбированных на гидроокиси алюмини
CN1276093C (zh) * 2001-05-15 2006-09-20 李卫云 一种检测丙肝病毒RdRp酶的方法，和载体以及用其转化的细胞株及应用

Also Published As

Publication number Publication date
AU2004269076B2 (en) 2007-09-20
CN1829917A (zh) 2006-09-06
CA2532726C (en) 2013-03-12
EP1649287A1 (de) 2006-04-26
MXPA06001382A (es) 2006-08-25
CA2532726A1 (en) 2005-03-10
DE602004015611D1 (de) 2008-09-18
KR101132439B1 (ko) 2012-03-30
PL1649287T3 (pl) 2009-04-30
WO2005022157A1 (en) 2005-03-10
ATE403867T1 (de) 2008-08-15
EP1649287B1 (de) 2008-08-06
CN1829917B (zh) 2010-08-25
AU2004269076A1 (en) 2005-03-10
KR20060126892A (ko) 2006-12-11
HK1094036A1 (en) 2007-03-16
ES2310732T3 (es) 2009-01-16

Similar Documents

Publication Publication Date Title
ATE188487T1 (de) Anti-gp39 antikoerper und deren verwendungen
BR0207067A (pt) Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo
HUP0303134A3 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1157042T3 (da) Fremstilling af tetravalente antistoffer
BRPI0111682B8 (pt) suporte sólido de imunoensaio, kit de teste de imunodiagnóstico, métodos de produção de um suporte sólido de imunoensaio, e de detecção de infecção pelo vírus da hepatite c (hcv) em uma amostra biológica, e, uso de um suporte sólido de imunoensaio
BRPI9911389B8 (pt) peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
DE60129278D1 (de) Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
DE602004015611D1 (de) Evaluierung adjuvanshaltiger impfstoffe
DK0797452T3 (da) Modulering af immunreaktionen
BR0011449A (pt) Método para detectar sìfilis usando antìgenos sintéticos
ID20581A (id) Antigen rotavirus, vaksin dan agen diagnostik untuk infeksi rotavirus, serta metode untuk menghasilkan antigen
WO2003046140A3 (en) Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
CA2433069A1 (en) Latent human tuberculosis model, diagnostic antigens, and methods of use
WO2005078450A3 (en) Method for the detection of early b cell populations in vaccine development
EA200700345A1 (ru) Обогащённое антитело для выявления микобактериальной инфекции, способы применения и диагностические тесты, применяющие такое антитело
CA2350340A1 (en) B-cell epitopes of hsp65 and uses thereof
EP1425301B1 (de) Therapeutische impfzusammensetzung zur verhütung und behandlung von erkrankungen bei säugetieren
WO2007005627A3 (en) Tuberculosis antigen detection assays and vaccines
RU2006112203A (ru) Экспресс-тест для диагностирования болезни альцгеймера
WO1998036089A3 (de) Testkit für tuberkulosediagnose durch bestimmung von alanindehydrogenase
DE69937258D1 (de) Genetische impstoffe mit adjuvans
Shimizu et al. Frequency of serological cross-reactions between Ibaraki and bluetongue viruses using the agar gel immunodiffusion test
Haaheim et al. Antibodies from lymphocytes used as diagnostic markers: a novel approach